US03753U1060 - Common Stock - After market: 46.88 0 (0%)
NASDAQ:APLS (12/6/2022, 7:21:42 PM)-2.5 (-5.06%)
|GICS Sector||Health Care|
|Earnings (Last)||11-07 2022-11-07/amc||Earnings (Next)||02-27 2023-02-27|
|Ins Owners||14.2%||Inst Owners||87.78%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic and complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company is headquartered in Waltham, Massachusetts and currently employs 476 full-time employees. The company went IPO on 2017-11-09. The firm is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, cold agglutinin disease, and hematopoietic stem cell transplantation thrombotic microangiopathy. The firm's advanced clinical programs targeting component 3 with Phase III clinical trials of its lead product candidate, pegcetacoplan, in multiple indications. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for ophthalmological administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.
APELLIS PHARMACEUTICALS INC
100 Fifth Avenue
Waltham MASSACHUSETTS 02451
CEO: Cedric Francois
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...
The delay is at Apellis' behest. The company wanted to include updated data in its request.
Apellis Pharmaceuticals (APLS) said the U.S. Food and Drug Administration (FDA) accepted the company's additional data filed for an application seeking approval...
WALTHAM, Mass., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in...
Here you can normally see the latest stock twits on APLS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.